top of page
Pharma & Healthcare
Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.
The Target's Playbook: How a Startup Actually Gets Acquired by Big Pharma
Getting acquired well isn't luck — it's the result of decisions made years earlier. Using SEC filings from Seagen, Avidity Biosciences, and Verona Pharma, this piece walks through exactly how founders identify the right buyer, price their asset, and negotiate from strength instead of desperation.
Jul 14
AI Can Out-Invent Big Pharma. It Still Can't Out-Build It.
AI in pharma is often described as one trend. It's really two, and it only wins one on its own merits. In drug discovery, AI directly attacks the problem of finding the right molecule, letting small teams compete with giants using nothing but data and talent. In drug manufacturing, AI can't shortcut anything, since it depends on years of proprietary production data that only exists once a company has already built an expensive facility, for reasons that have nothing to do wit
Jul 10
From Pills to Living Cells: Why Pharma Builds So Many Kinds of Drugs, and How Complex Each One Really Is
From a chemically synthesized pill to a patient's own genetically engineered living cells, drug modalities span an enormous range of manufacturing difficulty. This article explains why the pharmaceutical industry needs so many different approaches in the first place, then ranks every major modality, from small molecules to gene therapy, by how hard it actually is to build, and why.
Jul 10
Antibody-Drug Conjugates: Why Big Pharma Is Betting Billions on the Hardest Drug to Build
Antibody-drug conjugates are among the most complex drugs ever built, combining an antibody, a chemical linker, and a toxic payload into a single guided-missile therapy for cancer. That complexity hasn't stopped pharmaceutical giants from spending tens of billions of dollars chasing the technology. This article breaks down why ADCs are so hard to manufacture, why Japan's Daiichi Sankyo has built the strongest platform in the field, and how a newly approved bispecific ADC out
Jul 10
Who Funds What: A Map of Startup Capital from Angel to Wall Street
Angel checks range $25K-$350K, VC spans $500K seed to $200M late-stage, PE requires $50M+ ARR — and investment banks aren't investors at all. A full map of who funds what, at each stage, and how to actually reach them.
Jun 22
One Pandemic, Two Bets, Opposite Outcomes
Moderna had no patent, no clinical data — just one peer-reviewed paper. J&J's vaccine used a far more mature, proven platform, and was pulled after $1.5B in losses. Why the safer-looking bet doesn't always win.
Jun 21
AI in Pharma's Quiet Wins: Clinical Trials and Manufacturing
AI drug discovery has one validated success and zero FDA approvals so far — while AI in trial design already has formal regulatory qualification from both the EMA and FDA. The most-hyped application in pharma AI isn't the one furthest along.
Jun 14
AI in Pharma: Separating Proven Results from Promising Platforms
AlphaFold won a Nobel Prize, but its own drug pipeline hasn't dosed a single patient. Meanwhile, a 21-day AI-designed molecule just posted real Phase IIa results in Nature Medicine. A clear-eyed look at what's proven versus still promised.
Jun 14
Cell and Gene Therapy Is Not Dead —It Is Being Rebuilt From the Ground Up
Cell and gene therapy generated over $14B in 2024, yet pharma spent $10B+ acquiring pre-commercial companies in just seven months. The "CGT is dead" narrative confuses a broken pricing model with failed science — the biology already works.
Jun 1
Who Funds Science-Driven Companies — and Who Actually Does the Science
Investment banks can't predict whether a drug will work — 50-70% of Phase 2 drugs fail before Phase 3, yet banks price pre-Phase 3 biotech IPOs on a 16-20 week timeline anyway. VC, IB, and PE each play a genuinely different role — only one is actually built to judge the science.
Jun 1
bottom of page